CGparin

CGparin is a synthetic, heparin-like glycosaminoglycan designed for research purposes to model the anticoagulant properties of natural heparin while providing a defined, reproducible composition. The name reflects its origin as a chemically generated parin analogue. CGparin is not approved for clinical use and is intended for in vitro studies, reagent development, and enzymology experiments to understand anticoagulation mechanisms.

Chemistry and production: CGparin consists of sulfated polysaccharide chains based on a defined repeating disaccharide unit derived from heparin-like backbones. Its sulfation pattern and molecular weight are controlled to yield a predictable activity profile. It is produced by chemoenzymatic synthesis or controlled depolymerization of larger glycosaminoglycans followed by targeted sulfation, enabling consistent batch-to-batch activity. The compound is typically supplied as a dry powder or solution for research use.

Mechanism and applications: CGparin exerts anticoagulant effects primarily by enhancing the activity of antithrombin III, inhibiting thrombin (IIa) and factor Xa. The extent of IIa versus Xa inhibition depends on chain length and sulfation pattern. In vitro, it is used to study coagulation assays, antithrombin interactions, and to compare with natural heparin analogues. It is not intended for therapeutic use, and dosing guidance is limited to laboratory experimentation.

Safety and regulation: As a research reagent, CGparin is not approved for clinical administration. Researchers should follow standard laboratory safety practices for handling anticoagulants, including appropriate personal protective equipment and proper disposal. Compliance with institutional, national, and international regulations for chemical reagents applies.